Contract notice: Pharmaceutical products Tender, Germany - 34012036

Procurement Summary

Country : Germany

Summary : Contract notice: Pharmaceutical products

Deadline : 05 Jun 2021

Other Information

Notice Type : Tender

TOT Ref.No.: 34012036

Document Ref. No. : 286449-2019

Competition : ICB

Financier : Self Financed

Purchaser Ownership : -

Tender Value : Refer Document

Purchaser's Detail

Name :Login to see tender_details

Address : Login to see tender_details

Email : Login to see tender_details

Login to see details

Tender Details

Object of the contract
Pharmaceutical products

Description: Contract notice: Pharmaceutical products

Authority Type: Body governed by public law
Contact Nature: Supplies
Procedure: Open procedure
Document: Contract notice
Regulation: European Union
Award criteria: Lowest price
CPV code: 33600000, 33600000
CPV Description: Pharmaceutical products.

Conclusion of a non-exclusive discount agreement according to - 130a Abs. 8 SGB V on the active ingredient bimatoprost timolol, ATC S01ED62), for the period 1.8.2019 31.7.2020 (extension option 2 x 6 months)

Reference Number: 1002648 - Bimatoprost Timolol, ATC S01ED62

Section 130a (8) SGB V allows health insurances and pharmaceutical companies, framework discounts on die to be paid at the expense of the statutory health insurance companies. In view of the pertinent legal regulations for the awarding of public contracts, a regular process of active substance-related, public procurement procedures takes place according to the regulations of the 4th part of the GWB by the DAK-G. For the tenderer to be named in Appendix 2 to the contractMedicinal products for the active substance bimatoprost Timolol, ATC S01ED62, the DAK-G intends to conclude drug discount agreements with all interested pharmaceutical companies, pending the entry into force of new drug rebates. A discount contract within the scope of the approval model for the o. G. Active ingredient enters into force on 1.8.2019 for the first time and ends on 31.7.2020 (Verlaengeruoptional 2x 6 months). It automatically ends when the exclusive agreement comes into force.

DAK-Gesundheit ("DAK-G") assumes that this procedure does not fall within the scope of antitrust law due to the lack of a selection decision and thus the non-discriminatory accessibility of all pharmaceutical companies. He ends up independent of itautomatically with the entry into force of the exclusive contract for Bimatoprost Timolol, ATC S01ED62, as a result of a public procurement procedure in accordance with the regulations of Part 4 of the GWB with one or more contractual partners. In order to cope with the diversity of potential contract partners within the framework of the approval model, every pharmaceutical company will be awarded the contract during the contract periodframework agreement at any time and under the same conditions. The contract documents required for this are available via the online portal www.dtvp.de/center under the subsection I.3. The conditions for the conclusion, or the later accession to the contracts, which enter into force on 1.8.2019, are the complete and timelySending the following proofs / statements / attachments (available for download under the link mentioned under I.3.) to the following contact person at DAK-G:

1) Offer letter;

2) Current proof of enrollment in the profession or profession Commercial register (see III.1.1.)

3) Self-declaration by the company (Annex A1) that none of the exclusion criteria according to -- 123, 124 GWB(4) self-declaration that for those medicinal products for which the prospective buyer wishes to conclude a contract under this procedure, there is a drug license and that the bidder is entitled to sell at the inception of the contract (Appendix A2) (see III.1.1.);

5) self-declaration by the company that the legal requirements for the minimum wageand adhering to the tariff fidelity (Annex A3) (see III.1.1.);

6) Recognition of the contractual stipulations of the DAK-G, in particular the prescribed discounts by signing the contract stamped with a company stamp (2-fold in the original) by the interested party at the designated place;

7) Attachments 1 and 2 to the contract (twice each in the original). The prospect hashere the medicines to the o. g. 8) Effective pre-qualification notification of DAK-G (see III.1.1 and III.1.2.)

The documents must be submitted by post to:

DAK-Health

Henri Affinass (0032 50)

Nagelsweg 27-31

20097 Hamburg

Furthermore, the attachment 2 as an Excel file at the same time to the mail address am_rabattvertraege @ dak.de send. Contracts under this model and to o. G. The active substance will be concluded for the first time with effect from 1.8.2019 and will end on 31.7.2020 (extension option 2x 6 months). Interested parties who want to become contract partners for this date, have the o. G. Documents until the 5th of the previous month at o. G. Submit job. It depends on the timely access at the DAK-G an. For the deadline is an electronic receipt of the complete documents to the above. E-mail address is sufficient. Later accessions are possible at any time. In order to be able to join during the term of the contract on the 1st or 15th of the following month, the o. G. Documents, regardless of the desired accession, the DAK-G are available until the 5th of the previous month. Eg the one from the bidderIf you wish to join, you have to go to 15.07.20x (following month), the documents have to be available until 05.06.20x (previous month).

Note: The publication is done here using the form for open procedures. As already made clear, this is not one - the announcement had to be used for technical reasons, as it was not for Zulas

1) Current proof of registration in the professional or commercial register (not older than 6 months in the case of consignment) in accordance with the legislation of the country in which the company is established, eg. Eg current commercial register extract; Copy is sufficient.

2) Self-declaration of the company, that none of the exclusion criteria according to -- 123, 124 GWB is present. Attachment A1 must be signed, stamped with a company seal and submitted in the original.

3) Self-declaration that a medicinal product authorization is available for those medicinal products for which the prospective buyer wishes to conclude a contract under this procedure and that the bidder must The beginning of the contract for distribution (Annex A2) (see III.1.1.).

4) Self-declaration by the company that the legal requirements for minimum wages and remunera- tion of fees are observed and adhered to (Annex A3). Attachment A3 has to be signed, stamped with company stamp and submitted in original form.

DAK-Gesundheit has created a so-called pre-qualification procedure for pharmaceutical companies via the European announcement platformr published the simplified participation in future drug rebate tenders (EU Notice 2015 / S 105-190319 of 3.6.2015). If the bidder has received an effective pre-qualification notification from DAK-Gesundheit in good time prior to submission of the documents, he will need the company-specific proof of suitability (proof of registration in the trade or professional registerself-declaration of the company that none of the exclusion criteria acc. -- 123, 124 GWB is present, certificate of health insurance from the statutory health insurance, self-declaration minimum wage and tariff fidelity) under reference and enclosing the Praequalifikationsbescheides in copy no longer to be enclosed. Attachment A2 must always be attached. The pre-qualification notification of DAK-GesundheitAccordingly, it also serves as proof of DAK health open-house procedures, regardless of the value of the contract.

Self-declaration that for those medicinal products for which the prospective buyer wishes to conclude the contract under this procedure, there is a drug license and that the bidder is entitled to distribution at the beginning of the contract. For this purpose, Annex A2 is toosign, stamp with company name and submit in original. DAK-Gesundheit has published a so-called pre-qualification procedure for pharmaceutical companies for the simplified participation in future drug rebate tenders via the European Announcement Platform (EU Announcement 2015 / S 105-190319 of 3.6.2015). If the bidder timely voIf the documents submitted have received an effective pre-qualification notification from DAK-Gesundheit, it needs the company-specific proof of eligibility (proof of registration in the trade or professional register, self-declaration by the company that none of the exclusion criteria according to -- 123, 124 GWB is present) the statutory health insurance, Eigenerklaeminimum wage and tariff fidelity) with reference and enclosing the Praequalifikationsbescheides in copy no longer to be attached. Attachment A2 must always be attached. The pre-qualification notification from DAK-Gesundheit also serves as proof in open-house procedures of DAK-Gesundheit.

The tender documents can also be sent by e-mail in the case I.1. genacontact office. The tender documents will then be sent by e-mail. Questions and information on the tender documents are available electronically (by means of the bidder communication via the allocation portal www.dtvp.de) or in necessary individual cases by e-mail or in writing (by fax or letter) to those under I.1. to be addressed. You are in dto formulate Eutscher language. Answers will be made available to all entrepreneurs who have requested the tender documents by means of a registration in anonymous form. The answers are provided to the entrepreneurs by way of bidder communication via the allocation portal www.dtvp.de. Company that downloads the tender documents without registrationhave the responsibility to pursue the further communication on their own responsibility and if necessary to the o. g. This publication does not constitute a public service contract within the meaning of the 2014/24 / EU Procurement Coordination Directive of the European Parliament and of the Council or of the Public Procurement Law. To a maximum extent of TraIn order to ensure transparency for the envisaged contracts, it will be published in the Supplement to the Official Journal of the European Union. In the absence of a corresponding publication form, the contract notice will be used. The resulting conceptual requirements, such as the process name "Open Method", are solely the use of this Benotification form and the publication platform. A further meaning, in particular a submission under procurement regulations, as far as they are not obligatory for legal reasons, is not connected with this.

Announcement ID: CxP4YM5Y1HF


Internet address (URL): www.dak.de

Documents

 Tender Notice